The Role of Neuropeptide Y in the Expression and Extinction of Fear-Potentiated Startle
Open Access
- 26 November 2008
- journal article
- research article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 28 (48) , 12682-12690
Abstract
Neuropeptides are a promising target for novel treatments for anxiety and other psychiatric disorders and neuropeptide Y (NPY) has emerged as a key component of anxiolytic circuits in the brain. For this reason, we have evaluated the role of NPY in the expression and extinction of conditioned fear. We found that intracerebroventricular administration of NPY inhibits both baseline acoustic startle and the expression of fear-potentiated startle. Infusion of NPY (10 pmol/side) into the basolateral, but not the medial, nucleus of the amygdala reproduced the intracerebroventricular effect. Central administration of NPY (10 μg) also enhanced within-session extinction of fear-potentiated startle. This finding, coupled with the growing body of literature correlating NPY with resilience in humans, led us to the hypothesis that NPY may enhance the extinction of conditioned fear. When NPY (10 μg) is administered intracerebroventricularly before extinction training, extinction retention for both the contextual and cued components of conditioned fear is enhanced when tested 48 h later off drug. Additionally, we found that intra-basolateral amygdala administration of the NPY Y1receptor antagonist BIBO 3304 (200 pmol/side) before extinction training led to a profound deficit in extinction retention. This is the first evidence that NPY facilitates and an NPY antagonist blocks the extinction of conditioned fear. We believe that the role of NPY in the extinction of conditioned fear may, at least in part, explain the mechanism underlying the association between NPY and psychobiological resilience in humans.Keywords
This publication has 48 references indexed in Scilit:
- Neuropeptide Y in the Amygdala Induces Long-Term Resilience to Stress-Induced Reductions in Social Responses But Not Hypothalamic–Adrenal–Pituitary Axis Activity or HyperthermiaJournal of Neuroscience, 2008
- Acquisition of Fear Extinction Requires Activation of NR2B-Containing NMDA Receptors in the Lateral AmygdalaNeuropsychopharmacology, 2007
- Anxiolytic-like effect of the selective Neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-mazePeptides, 2006
- Mechanisms of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Arcuate NucleusJournal of Neuroscience, 2005
- Glutamate receptor antagonist infusions into the basolateral and medial amygdala reveal differential contributions to olfactory vs. context fear conditioning and expressionLearning & Memory, 2005
- Effects of Altered Amygdalar Neuropeptide Y Expression on Anxiety-Related BehaviorsNeuropsychopharmacology, 2005
- In the Amygdala Anxiolytic Action of mGlu5 Receptors Antagonist MPEP Involves Neuropeptide Y but not GABAA SignalingNeuropsychopharmacology, 2003
- Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodentsBritish Journal of Pharmacology, 1998
- Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startleBehavioral and Neural Biology, 1993
- The design and calibration of a startle measurement systemPhysiology & Behavior, 1986